Actively Recruiting
Postprandial Glucose Handing in Contraceptive and IUD Users
Led by McMaster University · Updated on 2025-09-22
54
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Goals: The long-term use of hormonal birth control has been shown to effect glucose handling, or blood sugar regulation, and potentially lead to insulin resistance which increases a person's risk for metabolic diseases such as type 2 diabetes. The goal of this study is to investigate how the body handles glucose, in three groups of young, healthy females: NAT (naturally cycling, or not using hormonal birth control), OCP (taking a birth control pill), and IUD (using an intrauterine device). Objectives: We will investigate if the body's ability to handle glucose differs between these groups. We will also explore if these differences are linked to the levels of primary sex hormones in females, estrogen and progesterone, and if the synthetic versions produced by hormonal birth control have the same negative effect. We will use an oral glucose tolerance test to investigate these potential differences, having participants drink a 75 gram glucose beverage and taking blood samples every 15-30 minutes for a 2-hour timespan. These blood samples will be used to measure glucose and insulin levels in the blood to determine any changes that occur in the body in response to glucose.
CONDITIONS
Official Title
Postprandial Glucose Handing in Contraceptive and IUD Users
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged between 18 and 45 years
- Body mass index (BMI) between 18.5 and 30.0 kg/m2
- Weight stable within plus or minus 2 kg for the past 6 months
- VO2peak values ranging from below average to above average
- Fasting blood glucose less than 6.0 mmol
- Resting blood pressure less than 140/90 mmHg
- For NAT females: regular menstrual cycles lasting 21 to 35 days for more than 6 months
- For OCP users: use of combined oral contraceptive pills with second generation levonorgestrel, monophasic formulations only, prescribed for more than 3 months
- For IUD users: hormonal levonorgestrel-releasing IUD (Kyleena or Mirena) inserted at least 3 months before the study
You will not qualify if you...
- Smoking
- Diagnosis of diabetes, cancer, or other metabolic disorders
- Cardiac or gastrointestinal problems
- Infectious disease
- Barium swallow or nuclear medicine scan within the past 3 weeks
- Pregnant or breastfeeding
- Diagnosis of polycystic ovary syndrome
- Endometriosis
- Use of emergency contraception (e.g., Plan B) within the past 3 months
- For NAT females: use of any hormonal contraceptive in the past 3 months
- For OCP users: inconsistent use or use longer than 3 years
- For IUD users: Kyleena IUD inserted longer than 2 years or Mirena IUD inserted longer than 4 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
McMaster University, Ivor Wynne Centre
Hamilton, Ontario, Canada, L8S 4K1
Actively Recruiting
Research Team
K
Kirsten E Bell, Ph.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here